在BRAF-V600突变转移性黑色素瘤中对二线尼沃卢马布和伊皮利穆马布的剧烈反应
Dahlia Fedele1, Stefano Moroso1, Angelo Turoldo2
1Department of Medical Oncology, ASUGI, Maggiore Hospital, Trieste, Italy.
Case reports in oncology
|January 30, 2024
概括
与尼沃卢马布和伊皮利穆马布的联合免疫疗法在晚期黑色素瘤中显示出有前途. 这种方法,特别是作为一线治疗,可以克服对BRAF/MEK抑制剂的耐药性,改善患者的生存结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 目前BRAF V600突变不可切除的III/IV期黑色素瘤的治疗方法包括抗PD-1,抗CTLA-4,抗LAG-3药物,BRAF/MEK抑制剂和临床试验.
- 与尼沃卢马布和伊皮利穆马布的联合免疫疗法显示出更高的反应率,反应持续时间,无进展的生存率和整体生存率.
相关概念视频
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K